EYPT - ピ―シビダ （EyePoint Pharmaceuticals Inc.）EYPTのニュース
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call Transcript 2022/08/03 19:05:18 Seeking Alpha
EyePoint Pharmaceuticals, Inc. (NASDAQ:NASDAQ:EYPT) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker -…
EyePoint Pharmaceuticals Reports In-Line Q2 EPS By Investing.com 2022/08/03 11:30:03 Investing.com
EyePoint Pharmaceuticals Reports In-Line Q2 EPS
EyePoint Pharmaceuticals GAAP EPS of -$0.52 misses by $0.01, revenue of $11.6M beats by $0.74M (NASDAQ:EYPT) 2022/08/03 11:01:41 Seeking Alpha
EyePoint Pharmaceuticals press release (EYPT): Q2 GAAP EPS of -$0.52 misses by $0.01.Revenue of $11.6M (+28.7% Y/Y) beats by $0.74M."We expect the cash, cash equivalents and…
Earnings Preview For EyePoint Pharmaceuticals 2022/08/02 18:41:42 Benzinga
EyePoint Pharmaceuticals (NASDAQ: EYPT ) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here''s what investors need to know before the announcement. Analysts estimate that EyePoint Pharmaceuticals will report an earnings per share (EPS) of $-0.52. EyePoint Pharmaceuticals bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences 2022/08/02 11:00:00 GlobeNewswire
WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals’ will present at the following upcoming conferences:
EyePoint Pharma Secures $45M Credit Facilities For Debt Refinancing 2022/03/09 17:18:02 Benzinga
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT ) has secured senior secured credit facilities of $45 million from Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC . Under the terms of the new agreement, a $30 million term loan facility and an asset-based revolving credit … Full story available on Benzinga.com
EyePoint Pharmaceuticals signs loan agreement for $45M with Silicon Valley Bank 2022/03/09 12:47:51 Seeking Alpha
EyePoint Pharmaceuticals (EYPT) entered into a loan agreement providing for senior secured credit facilities in the amount of $45M with Silicon Valley Bank to replace its existing…
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2021 Results - Earnings Call Transcript 2022/03/03 20:10:06 Seeking Alpha
DBV Technologies, EyePoint top healthcare gainers; NuCana, MediWound lead losers'' pack 2022/03/03 15:00:42 Seeking Alpha
DBV Technologies DBVT +16%. EyePoint Pharmaceuticals (EYPT) +14%. NuCana (NCNA) -54%. MediWound (MDWD) -15%.
EyePoint Pharmaceuticals GAAP EPS of -$0.59 misses by $0.03, revenue of $11.54M beats by $1.75M 2022/03/03 12:02:40 Seeking Alpha
EyePoint Pharmaceuticals press release (EYPT): Q4 GAAP EPS of -$0.59 misses by $0.03.Revenue of $11.54M (+61.9% Y/Y) beats by $1.75M.
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call Transcript 2021/11/03 16:27:05 Seeking Alpha
EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments 2021/11/03 11:00:00 Intrado Digital Media
– Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) –
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer 2021/11/01 11:00:00 Intrado Digital Media
WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO). Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of EyePoints Board of Directors since 2016. In his new full-time role as COO, Dr. Duker will be responsible for overseeing all clinical development, research, product development and manufacturing.
Head-To-Head Analysis: EyePoint Pharmaceuticals (NASDAQ:EYPT) & Cytek BioSciences (NASDAQ:CTKB) 2021/10/30 13:20:49 Dakota Financial News
EyePoint Pharmaceuticals (NASDAQ:EYPT) and Cytek BioSciences (NASDAQ:CTKB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Profitability This table compares EyePoint Pharmaceuticals and Cytek BioSciences net margins, return on equity and return []